Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection.

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The purpose of the study is to compare the efficacy, safety and recurrence rate of two therapeutic strategies with ribavirin in patients with chronic hepatitis E and severe acute hepatitis E: fixed duration of treatment for 12 weeks vs variable duration depending on the viremia within 4 weeks of the start of treatment (12 vs 24 weeks). The purpose of the study is also improve the safety of treatment with Ribavirin by optimizing dose adjusted to renal function, plasma levels of drug and hemoglobin.
Epistemonikos ID: 7af9b94488d15710a2cb5a0ba3f542339d6534c8
First added on: Mar 23, 2020